SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending after announcing a partnership with Perplexity AI to enhance content discovery and bundle services, sparking community excitement about AI integration. Discussions also revolve around Rumble's ties to cryptocurrency through Tether and potential benefits from a Trump administration. Some traders are eyeing a potential short squeeze given the high short interest.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a recent surge in quantum computing stocks, fueled by a $5.7 million sale of two quantum computers. Community discussions revolve around the stock's high valuation and potential for a short squeeze, with bullish investors targeting higher prices while bears anticipate a significant correction. The broader context involves the rapidly growing quantum computing sector and its speculative nature.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users highlight its association with weed culture and its potential for growth, drawing comparisons to Bitcoin. Community members emphasize Weedcoin's focus on freedom, natural growth, and cultural connection, promoting it as more than just a cryptocurrency. Discussions also involve community links and contract addresses.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid general excitement in the quantum computing sector, with community members highlighting its potential for energy-efficient solutions. Some traders are discussing potential breakouts and short squeezes, while others compare QBTS to other quantum and AI stocks. Recent news and government initiatives in quantum tech appear to be driving interest.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending with mixed sentiment after a report highlighted security flaws in a battlefield comms prototype, triggering a community debate. While some see it as a buying opportunity amidst a euphoric bull market, others question its valuation and potential government contract impacts. The community is actively discussing whether to buy the dip or wait for further developments.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending as traders discuss its potential for a squeeze, with some anticipating a rise to $10 or even $20. This speculation follows news of FDA Fast Track designation for ALTO-101 and investors are actively monitoring chat rooms, hoping for a breakout. The community also discusses the company's financials, pipeline and potential readouts.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the quantum computing sector gains momentum, with community members actively discussing its potential and comparing it to other players like $QBTS and $RGTI. Bullish sentiment is fueled by the company's collaborations, and some traders anticipate a short squeeze as the stock approaches all-time highs. Others remain skeptical, pointing to valuation concerns and the long-term horizon for quantum computing commercialization.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as community members discuss the potential impact of recent news, including a private placement, on the stock. Some are optimistic about the company's future and potential government backing, while others express concerns about revenue and valuation, leading to a debate on the stock's prospects. Trading volume and options activity are elevated compared to average levels.

Epsium Enterprise Ltd. operates as a holding company, which engages in import trading and distribution of wines and spirits. It offers a range of products, including Chinese liquor, French cognac, Scottish whisky, fine wines, champagne, and other miscellaneous alcoholic beverages. Its brands include Moutai, Xijiu, Wuliangye, Remy Martin Cognac, Macallan, Cointreau, Piper Heidsieck Champagne, French Fine Wines, Red and White Wines. The company was founded by Son I Tam on March 24, 2020 and is headquartered in Macau.

Epsium Enterprise Ltd. - Ordinary Shares - Class A

Epsium Enterprise Ltd.

Epsium Enterprise Ltd. ($EPSM) is trending due to a volatile trading pattern, marked by frequent trading halts and significant price swings, reminiscent of other high-flying stocks. Community chatter revolves around whether the stock is a pump-and-dump scheme, with some anticipating a massive sell-off while others hope for continued upward momentum. The stock's connection to the Chinese booze market and its small float are also fueling speculation and trading activity.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending as traders discuss its potential for continuation and speculate on government support following news of White House talks. Some community members are drawing parallels to previous rare earth stock surges, while others point to the company's expansion into AI data center power and modular revenue growth as catalysts. Discussions also mention short interest and potential for a squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street analysts downgraded Regulus Therapeutics on Wednesday following its acquisition by Swiss drugmaker Novartis, citing limited room for upside after the deal valued Regulus at up to $1.7 billion.JonesResearch cut its rating to ‘Hold’ from ‘Buy’ and lowered its price target to $7 from $8, calling the offer “highly favorable” in light of Regulus’ upcoming Phase 3 trial financing needs, according to The Fly.Canaccord Genuity also&nbsp;reportedly downgraded the stock to ‘Hold,’ slashing its target to $11 from $28.&nbsp;Meanwhile,&nbsp;Wells Fargo reportedly cut its rating on Regulus to ‘Equal Weight’ from ‘Overweight,’ raising its target to $9 from $6 to reflect the contingent value right (CVR) component. Leerink Partners and Oppenheimer issued similar downgrades.Under the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/regulus-therapeutics-stock-rockets-on-novartis-buy-offer/chXTfRKRbiP">agreement</a>, Regulus shareholders will receive $7 per share in cash and an additional $7 via a CVR, contingent on U.S. regulatory approval of its lead candidate, farabursen.&nbsp;The upfront payment represents a 108% premium to Regulus’ April 29 closing price and a 274% premium to its 60-day volume-weighted average.&nbsp;The transaction, unanimously approved by both companies’ boards, is expected to close in the second half of 2025, pending regulatory approvals and majority shareholder tender.Shares of Regulus surged to their highest levels since 2021 following the news and are up 6.4% year-to-date, while Novartis has gained 4.8%, both outperforming broader markets.The Dow is down 4.1%, the S&amp;P 500 has lost 5.1%, and the Nasdaq is off 1.6% over the same period.On Stocktwits, 24-hour message volume for Regulus jumped by 2,863% amid “extremely bullish” sentiment.One user congratulated Regulus shareholders, particularly recent buyers, and suggested that the growing interest in rare diseases could make companies like Protalix BioTherapeutics, Zevra Therapeutics, and Esperion Therapeutics potential targets going forward.<stembedurl>https://stocktwits.com/OldManLogan/message/613115970</stembedurl>Another Stocktwits user speculated that Regulus shares could double from current levels, fueled by FDA-related optimism and the potential for a competing bid to top Novartis' offer.<stembedurl>https://stocktwits.com/ST_Tropez_Trading/message/613203730</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regulus Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.

Equity

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference PR Newswire CARMIEL, Israel, Feb...

Pluxee shares jump 11% on strong Q1 operating revenue growth

Investing.com -- Pluxee NV (EPA:PLX) reported 12.1% organic growth in first-quarter operating revenue, beating market expectations, and sending its shares soaring 11% in European trading Wednesday.

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE: PLX) (Protalix) on behalf of the companys shareholders. Since May 2023, shares of Protalix common stock have...

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference...

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

Protalix BioTherapeutics Inc.

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

PLX
Protalix BioTherapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PLX News

PLX Protalix BioTherapeutics Inc.